Prospective trial of nivolumab (Nivo) plus radium-223 (RA) in metastatic castration-resistant prostate cancer (mCRPC) evaluating circulating tumor DNA (ctDNA) levels as a biomarker of response.

Benjamin Louis Maughan,Roberto H. Nussenzveig,Umang Swami,Sumati Gupta,Neeraj Agarwal

Prospective trial of nivolumab (Nivo) plus radium-223 (RA) in metastatic castration-resistant prostate cancer (mCRPC) evaluating circulating tumor DNA (ctDNA) levels as a biomarker of response.

2020

Benjamin Louis Maughan
Roberto H. Nussenzveig
Umang Swami
Sumati Gupta
Neeraj Agarwal

TPS267Background: RA is a calcium-mimetic radiopharmaceutical emitter of alpha particles that has been approved for treatment of mCRPC. Radiation plus checkpoint inhibitors has demonstrated promisi...

Keywords:

Castration
Prostate cancer
Biomarker (medicine)
Oncology
Nivolumab
Pathology
Internal medicine
Circulating tumor DNA
Radium-223
Medicine
castration resistant
prospective trial
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations